Cherwell announces Andy Whittard’s retirement and names Stuart Hall as new Managing Director
Strong UK-based leadership team in place to drive customer and quality focused business forward and build on excellent legacy
Advertisement
Cherwell announced the retirement of Andy Whittard, Managing Director, and the appointment of Stuart Hall, Cherwell’s current Director of Finance, as his successor from 1st September 2025.
Leadership transition at Cherwell: Andy Whittard (right) retires as Managing Director and Stuart Hall (left), Cherwell’s current Director of Finance, appointed as his successor.
Andy’s 20-plus years’ tenure as Managing Director at Cherwell has seen significant growth and innovation within the business, and also achieved key milestones to secure the long-term future of the company as AnalytiChem UK from 1st September. A strong UK-based leadership team is in place to continue to drive the business forward and build on its deep customer focus and high-quality cleanroom microbiology products and services, for which Cherwell is renowned.
Stuart Hall will be heading the company’s UK leadership team at its Bicester-based ISO9001 registered facility, where it manufactures and supplies its Redipor® prepared culture media products. Stuart joined Cherwell in 2021, having worked within a range of manufacturing and service focused industries. In addition to his broad experience from previous roles, his deep understanding of the business, its people and customers makes him ideal to now guide Cherwell (as AnalytiChem UK) through its ongoing growth as a highly reliable and successful UK manufacturer and supplier of high-quality products.
Leading AnalytiChem UK, Stuart will oversee the development and enhancement of the company’s product and services offering, as well as its manufacturing facility, through continued investment in the business supported by the AnalytiChem Group’s wider global network. As part of his new role as AnalytiChem UK’s Managing Director, Stuart will also join the group’s global leadership team to facilitate shared expertise and discovery of associated opportunities.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases
GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026
Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership
WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership
Otto Warburg Medal 2026 awarded to Maya Schuldiner
Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years